公开(公告)号：US11254975B2

公开(公告)日：2022-02-22

申请号：US16421295

申请日：2019-05-23

Applicant: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT

Inventor： Toru Uchiyama ,  Masafumi Onodera

IPC: C12Q1/68 ,  C12Q1/6848 ,  C12Q1/682 ,  C12Q1/6851 ,  C12Q1/686 ,  C12Q1/6811 ,  C12Q1/6827

Abstract: A method of amplifying a target nucleic acid (polynucleotide) contained in a particle including an enclosing lipid bilayer membrane according to the present invention includes the steps of: lysing the particle which is stored in a compartment constituted by a liquid in an amount of 100 μl or less; and amplifying the target nucleic acid in the compartment.

公开(公告)号：US20220018832A1

公开(公告)日：2022-01-20

申请号：US16933835

申请日：2020-07-20

Applicant: GlycoTechnica Co. Ltd. ,  National Center for Child Health and Development

Inventor： Akihiro Umezawa ,  Koji Okamura ,  Mayu Shibata ,  Masao Yamada

IPC: G01N33/53 ,  G01N33/543 ,  G01N21/64 ,  G16H50/20

Abstract: The invention aims to provide a non-destructive method of testing and analysing, amongst other things, cell types such as pluripotent cells, including differentiated cells and MSCs. The invention also aims to provide a non-destructive method to test and analyse the cell conditions, such as aging, activity, multipotency, differentiated directivity and effectiveness. Possibility of analysing cell types or cell conditions without destroying the cells by analyzing glycan profile, which is acquired from glycoconjugates secreted from cells in culture mediums, using microarrays with glycan binding protein, on the surface was discovered.

公开(公告)号：US20200297674A1

公开(公告)日：2020-09-24

申请号：US16651238

申请日：2018-11-28

Applicant: SBI Pharmaceuticals Co., Ltd. ,  National Center for Child Health and Development

Inventor： Tohru Tanaka ,  Hidenori Ito ,  Ko Rii

IPC: A61K31/197 ,  C07K16/28 ,  A61K33/26

Abstract: The object of the invention is to provide a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor. Provided is a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor comprising 5-aminolevulinic acids (ALAs) as the active ingredient.

公开(公告)号：US10584314B2

公开(公告)日：2020-03-10

申请号：US15502321

申请日：2015-08-07

Applicant: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT ,  SENJU PHARMACEUTICAL CO., LTD.

Inventor： Noriyuki Azuma ,  Taku Tanaka ,  Tadashi Yokoi

IPC: C12N5/00 ,  C12N5/079 ,  C12N15/09 ,  C12Q1/02 ,  A61L27/00 ,  A61P27/06 ,  A61K35/30 ,  C12Q1/6876 ,  G01N33/50

Abstract: An object of the present invention is to provide a method of inducing pluripotent stem cells to differentiate into clinically applicable retinal ganglion cells.The present invention provides a method for inducing pluripotent stem cells to differentiate into retinal ganglion cells that can be used for clinical application. Such method is a method for producing retinal ganglion cells with elongated axons comprising the following steps: (a) a step of inducing pluripotent stem cells to differentiate into retinal progenitor cells via floating culture; (b) a step of inducing the retinal progenitor cells obtained in step (a) to differentiate into retinal ganglion cells via floating culture; and (c) a step of allowing axons to elongate via adhesion culture of the retinal ganglion cells obtained in step (b).

公开(公告)号：US20160289663A1

公开(公告)日：2016-10-06

申请号：US15037907

申请日：2014-11-17

Applicant: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT ,  NATIONAL CANCER CENTER ,  LSIP, LLC

Inventor： Nobutaka Kiyokawa ,  Kenji Matsumoto ,  Kenichiro Kobayashi ,  Hitoshi Ichikawa

IPC: C12N9/96 ,  C12N9/12 ,  G01N33/574 ,  A61K31/506 ,  C07K14/47

CPC classification number: C12N9/96 ,  A61K31/404 ,  A61K31/5025 ,  A61K31/506 ,  A61K45/06 ,  C07K14/4702 ,  C07K14/71 ,  C07K2319/00 ,  C12N9/12 ,  C12Y207/10001 ,  G01N33/502 ,  G01N33/57484 ,  G01N2500/00 ,  G01N2500/10 ,  A61K2300/00

Abstract: To identify a mutation that can serve as an indicator for predicting the effectiveness of drug treatment in cancers such as leukemia; to provide a means for detecting said mutation; and to provide a means for identifying, based on said mutation, patients with cancer or subjects with a risk of cancer, in whom a drug targeting a gene having said mutation or a protein encoded by said gene shows a therapeutic effect.A method for detecting a gene fusion serving as a responsible mutation (driver mutation) for cancer, the method comprising the step of detecting an ATF7IP-PDGFRB fusion polynucleotide or a polypeptide encoded thereby, in an isolated sample from a subject.

Abstract translation: 一种用于检测用于癌症的负责突变（驱动突变）的基因融合体的方法，该方法包括在受试者的分离样品中检测ATF7IP-PDGFRB融合多核苷酸或由其编码的多肽的步骤。

公开(公告)号：US20160206582A1

公开(公告)日：2016-07-21

申请号：US15064884

申请日：2016-03-09

Applicant: SBI Pharmaceuticals Co., Ltd. ,  National Center for Child Health and Development

Inventor： Ko RII ,  Kiwamu TAKAHASHI ,  Naomi HAGA ,  Fuminori ABE ,  Tohru TANAKA ,  Motowo NAKAJIMA ,  Hidenori ITO

IPC: A61K31/197 ,  A61K33/26 ,  A61K35/17

CPC classification number: A61K31/197 ,  A01N1/0226 ,  A61K31/22 ,  A61K31/295 ,  A61K33/26 ,  A61K35/17 ,  A61K45/06 ,  A61K2035/122 ,  A61K2035/124 ,  A61K2300/00

Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.

Abstract translation: 本发明提供了一种用于促进移植物存活的药剂，其可以抑制不使用现有的免疫抑制剂的排斥反应，能够保持从供体排出的器官的新鲜度的器官保存溶液等。 制备促进移植物存活的药剂或器官保存溶液，其包含5-氨基乙酰丙酸（ALA）或其衍生物，或ALA或其衍生物和铁化合物的盐作为活性成分。 ALA的优选实例可以包括ALA和各种酯，例如ALA的甲酯，乙酯，丙酯，丁酯和戊酯，以及它们的盐酸盐，磷酸盐和硫酸盐。 铁化合物的优选实例可包括柠檬酸亚铁钠。

公开(公告)号：US20150174090A1

公开(公告)日：2015-06-25

申请号：US14413151

申请日：2013-07-03

Applicant: SBI PHARMACEUTICALS CO., LTD. ,  National Center for Child Health and Development

Inventor： Tohru Tanaka ,  Motowo Nakajima ,  Fuminori Abe ,  Naomi Haga ,  Kiwamu Takahashi ,  Hidenori Ito ,  Ko Rii

IPC: A61K31/197 ,  A61K33/26

CPC classification number: A61K31/197 ,  A61K31/194 ,  A61K33/26 ,  A61K38/193 ,  A61K38/40 ,  C12N5/064 ,  C12N2500/24 ,  C12N2501/052 ,  C12N2501/22 ,  C12N2501/2304 ,  A61K2300/00

Abstract: An object of the present invention is to provide a regulatory dendritic cell inducing agent applicable to the treatment of immune disease as well as an immune tolerance inducing agent such as a preventive and/or therapeutic agent for allergic disease and a preventive and/or therapeutic agent for autoimmune disease, both of which are safe and have the mechanism of action different from that of conventional drugs. As a means for achieving the above object, an immune tolerance inducing agent comprising 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of the 5-ALA or the derivative and an iron compound as active ingredients is prepared. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.

Abstract translation: 本发明的目的是提供适用于免疫疾病的治疗的调节性树突状细胞诱导剂以及免疫耐受诱导剂，例如过敏性疾病的预防和/或治疗剂以及预防和/或治疗剂 对于自身免疫性疾病，两者都是安全的，并且具有与常规药物不同的作用机制。 作为实现上述目的的方法，制备包含5-氨基乙酰丙酸（ALA）或其衍生物或5-ALA或其衍生物和铁化合物的盐作为活性成分的免疫耐受诱导剂。 ALA的优选实例可以包括ALA和各种酯，例如ALA的甲酯，乙酯，丙酯，丁酯和戊酯，以及它们的盐酸盐，磷酸盐和硫酸盐。 铁化合物的优选实例可包括柠檬酸亚铁钠。

公开(公告)号：US12024714B2

公开(公告)日：2024-07-02

申请号：US16808170

申请日：2020-03-03

Applicant: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT ,  SENJU PHARMACEUTICAL CO., LTD.

Inventor： Noriyuki Azuma ,  Taku Tanaka ,  Tadashi Yokoi

IPC: C12N5/079 ,  A61K35/30 ,  A61L27/00 ,  A61P27/06 ,  C12N15/09 ,  C12Q1/02 ,  C12Q1/6876 ,  G01N33/50

CPC classification number: C12N5/0621 ,  A61K35/30 ,  A61L27/00 ,  A61P27/06 ,  C12N15/09 ,  C12Q1/02 ,  C12Q1/6876 ,  G01N33/5058 ,  C12N2501/13 ,  C12N2506/02 ,  C12N2506/08 ,  C12N2506/45 ,  C12Q2600/136 ,  C12Q2600/158

Abstract: An object of the present invention is to provide a method of inducing pluripotent stem cells to differentiate into clinically applicable retinal ganglion cells.
The present invention provides a method for inducing pluripotent stem cells to differentiate into retinal ganglion cells that can be used for clinical application. Such method is a method for producing retinal ganglion cells with elongated axons comprising the following steps: (a) a step of inducing pluripotent stem cells to differentiate into retinal progenitor cells via floating culture; (b) a step of inducing the retinal progenitor cells obtained in step (a) to differentiate into retinal ganglion cells via floating culture; and (c) a step of allowing axons to elongate via adhesion culture of the retinal ganglion cells obtained in step (b).

公开(公告)号：US11963974B2

公开(公告)日：2024-04-23

申请号：US16491435

申请日：2018-03-09

Applicant: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT ,  HIROSHIMA UNIVERSITY ,  DAIICHI SANKYO COMPANY, LIMITED

Inventor： Go Tajima ,  Satoshi Okada ,  Miyuki Tsumura

IPC: C12N15/11 ,  A61K31/7088 ,  A61K48/00 ,  A61P3/08 ,  C12N15/113

CPC classification number: A61K31/7088 ,  A61K48/00 ,  A61P3/08 ,  C12N15/113 ,  C12Y301/03009 ,  C12N2310/11 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2320/33

Abstract: The present invention provides a novel antisense oligonucleotide and a composition for preventing or treating glycogen storage disease type Ia. The present invention provides an antisense oligonucleotide which hybridizes with a pre-mRNA sequence derived from a region including at least one of a base at position 42911000, a base at position 42911004, and a base at position 42911005 in a base sequence of human chromosome 17 of GRCh38/hg38 and has activity to inhibit aberrant splicing of pre-mRNA of c.648G>T variant G6PC.

公开(公告)号：US20230160914A1

公开(公告)日：2023-05-25

申请号：US17766118

申请日：2020-10-02

Applicant: The University of Tokyo ,  NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT

Inventor： Takahisa Murata ,  Tatsuro Nakamura ,  Yuta Hamasaki ,  Yukihiro Ohya ,  Yusuke Inuzuka ,  Kiwako Yamamoto

IPC: G01N33/92 ,  C12Q1/6883

CPC classification number: G01N33/92 ,  C12Q1/6883 ,  C12Q2600/158 ,  C12Q1/6851

Abstract: An object of the present disclosure is to provide a novel method for detecting atopic dermatitis and a novel method for determining a therapeutic effect on atopic dermatitis. The present disclosure provides a method for detecting atopic dermatitis, including the step of measuring the concentration of a lipid metabolite in a biological sample of a subject. The present disclosure also provides a method for determining a therapeutic effect on atopic dermatitis, including the step of measuring the concentration of a lipid metabolite in a biological sample of a subject.